PBPK modeling for irbesartan in different CYP2C9 genotypes

被引：0
|
作者：
Kang, Pureum [1 ]
Cho, Chang-Keun [1 ]
Ko, Eunvin [1 ]
Mu, Chou Yen [1 ]
Lee, Seok-Yong [1 ]
机构：
[1] Sungkyunkwan Univ, Seoul, South Korea
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 2023年 / 180卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P0064
引用
收藏
页码：249 / 250
页数：2
相关论文
共 50 条
  • [31] Application of Vivid™ fluorogenic substrates for the in vitro assessment of CYP2C9*1, CYP2C9*2 and CYP2C9*3 metabolism
    Thompson, DV
    Marks, BD
    Goossens, TA
    Trubetskoy, OV
    DRUG METABOLISM REVIEWS, 2002, 34 : 153 - 153
  • [32] Analysis of CYP2C9 promotor variations and possible links to the CYP2C9*2 and CYP2C9*3 exon variants.
    Schubert, C
    Cubic, I
    Kirchheiner, J
    Brockmöller, J
    Roots, I
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (07) : S98 - S98
  • [33] CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population
    Xiumei Hong
    Shanchun Zhang
    Guangyun Mao
    Shanqun Jiang
    Yan Zhang
    Yunxian Yu
    Genfu Tang
    Houxun Xing
    Xiping Xu
    European Journal of Clinical Pharmacology, 2005, 61 : 627 - 634
  • [34] CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
    Pedro Dorado
    Roland Berecz
    Maria-Jesús Norberto
    Ümit Yasar
    Marja-Liisa Dahl
    Adrián LLerena
    European Journal of Clinical Pharmacology, 2003, 59 : 221 - 225
  • [35] CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
    Dorado, P
    Berecz, R
    Norberto, MJ
    Yasar, Ü
    Dahl, ML
    LLerena, A
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (03) : 221 - 225
  • [36] Functional characterization of the defective CYP2C9 variant CYP2C9*18
    Liu, Jian
    Chen, Hao
    Wang, Shuang-Hu
    Zhou, Quan
    Geng, Pei-Wu
    Zhou, Yun-Fang
    Wu, Hua-Lan
    Shi, Hai-Feng
    Wang, Fang
    Yang, Jie-Fu
    Cai, Jian-Ping
    Dai, Da-Peng
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (01):
  • [37] Metabolism of warfarin enantiomers in Japanese patients with different CYP2C9/2C19 genotypes.
    Takahashi, H
    Kubota, T
    Kimura, S
    Echizen, H
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 148 - 148
  • [38] Functional impact of CYP2C*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans
    Allabi, AC
    Gala, JL
    Horsmans, Y
    Babaoglu, MO
    Bozkurt, A
    Heusterspreute, M
    Yasar, U
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) : 113 - 118
  • [39] Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes
    Takahashi, H
    Kashima, T
    Nomizo, Y
    Muramoto, N
    Shimizu, T
    Nasu, K
    Kubota, T
    Kimura, S
    Echizen, H
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (05) : 519 - 528
  • [40] Prediction of Flurbiprofen Pharmacokinetics by CYP2C9 Genotypes in Populations Utilizing a Physiological Based Pharmacokinetic Modeling
    Shin, Hyo
    Lim, Chang
    Oh, Kyung
    Cho, Chang
    Jung, Eui
    Lee, Choong
    Byeon, Ji
    Lee, Seok
    FASEB JOURNAL, 2020, 34
12345